--- type: "firecrawl-provider" description: "Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API." use_when: "Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API.\n\nDrug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API.\n\nDrug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API.\n\nDrug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API.\n\nDrug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API." categories: "Health" capabilities: 5 credits_per_call: 5 --- # Open Targets Platform on Firecrawl Alexandria Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. - Categories: Health - Category index: [Health category](https://firecrawl.dev/alexandria/agents/categories/health) - Provider key: `platform-opentargets-org` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://firecrawl.dev/app/alexandria/platform-opentargets-org) - [OpenAPI spec](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/openapi.json) ## Capabilities - [List associations](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/associations/list_associations): Target-disease associations scored by Open Targets (0 to 1) with the score broken down by evidence type (genetic association, somatic mutation, known drug/clinical, pathways, RNA expression, literature, animal models) and by datasource. Give a target for its diseases (optionally within one therapeutic area), a disease for its targets, or both for one pair. Order by the overall score or one evidence type; `min_score` stops at a threshold. - [Get target](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/targets/get_target): One drug target (human gene) from Open Targets: approved symbol and name, Ensembl ID, biotype, synonyms and previous symbols, UniProt function text, genomic location, ChEMBL target class, tractability by modality (small molecule, antibody, PROTAC, other), subcellular locations, safety liabilities with effects, tissues and sources, chemical probes, gnomAD loss-of-function constraint, core essentiality, and UniProt, HGNC, ChEMBL and PDB cross-references. Accepts a symbol, Ensembl ID, UniProt accession, synonym or target page URL; `matched_on` says how the input matched. - [List drugs](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/drugs/list_drugs): Known drugs and clinical candidates from Open Targets clinical reports (ClinicalTrials.gov, FDA, EMA, PMDA, DailyMed, ChEMBL, TTD): for a target, the drugs acting on it with their indications; for a disease, the drugs developed for it; for both, the drugs for that disease that act on that target. Each row has the ChEMBL ID, name, type, highest harmonised clinical stage, mechanisms of action with their targets, and up to 5 supporting reports with IDs, status and links. Highest stage first; `min_stage` filters. - [List evidence](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/evidence/list_evidence): The evidence records behind one Open Targets target-disease association, highest score first: datasource and evidence type, score, the disease as the source named it, PubMed and PMC IDs, variant and rsID, GWAS study, drug and clinical stage, direction of effect on target and trait, ClinVar significance, p-value, odds ratio, beta, sample size and source links. Filter to chosen datasources. - [Search diseases](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/diseases/search_diseases): Search Open Targets diseases and phenotypes (EFO, MONDO, HP, Orphanet terms) by free text, or read one by ontology ID or disease page URL. Each result has its ID, name, description, therapeutic areas, exact synonyms, cross-references to other vocabularies (MeSH, DOID, ICD10, OMIM, UMLS) and the retired IDs it replaces. Retired EFO IDs (e.g. EFO_0000270) are followed to the current record through EBI OLS. ## 1. Choose this provider when Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. Drug-target evidence from the Open Targets Platform (EMBL-EBI, Wellcome Sanger Institute and partners; data CC0): target profiles with tractability, safety liabilities and cross-references; diseases and phenotypes across EFO, MONDO, HP and Orphanet with synonyms and vocabulary mappings; target-disease association scores broken down by evidence type and datasource; the evidence records behind them (GWAS, rare variants, somatic drivers, clinical precedence, literature); and known drugs and clinical candidates with mechanisms, clinical stage and trial or regulatory references. Targets resolve from symbols, synonyms and UniProt accessions, diseases from names and IDs, including retired EFO IDs. Uses the keyless Open Targets GraphQL API. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "platform-opentargets-org", "capability": "associations/list_associations", "options": { "limit": 10, "target": "BRAF" } } ``` ## 3. Add provider options Use only the options needed for the task: - `cursor` (string): `next_cursor` from the previous page. Repeat the same inputs and `limit` with it. Pattern: ^[0-9]+$. Example: `next_cursor` - `disease` (string): Disease or phenotype: an ontology ID (`MONDO_0004979`, `EFO_0000270`, `EFO:0000270`, `HP_0002099`, `Orphanet_558`), an exact name or exact synonym (`asthma`, `T2DM`), or a platform.opentargets.org disease page URL. Retired EFO IDs follow to their replacement with a `disease_replaced` warning; other names fail as not_found listing the closest matches (use `search_diseases` to browse). Example: `MONDO_0004979` - `indirect` (boolean): Include indirect evidence, which propagates evidence on a disease's descendants up to it (e.g. Crohn's disease evidence counts for inflammatory bowel disease). Defaults to false for a target's diseases and true when a disease is given, as on the Open Targets pages. Example: `false` - `limit` (number): Rows per page, 1 to 100. Example: `25` - `min_score` (number): Stop at rows whose ranking score (overall, or the `order_by` evidence type) is below this. Example: `1` - `order_by` (string): Rank by the overall score or by one evidence type's score, descending. Example: `score` - `target` (string): Target: an HGNC symbol (`BRAF`), Ensembl gene ID (`ENSG00000157764`), UniProt accession (`P15056`), previous symbol, synonym (`HER2`, `p53`), approved name, or a platform.opentargets.org target page URL. Ambiguous synonyms fail as invalid_input naming the candidates. Example: `` - `therapeutic_area` (string): Only a target's diseases in this therapeutic area: a name or words of it (`cancer`, `respiratory`, `immune system disorder`) or its ID (`MONDO_0045024`). Not with `disease`. Example: `` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "platform-opentargets-org", capability: "associations/list_associations", options: { limit: 10, target: "BRAF", }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "platform-opentargets-org", "capability": "associations/list_associations", "options": { "limit": 10, "target": "BRAF" } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "platform-opentargets-org", "capability": "associations/list_associations", "options": { "limit": 10, "target": "BRAF" } } }' ``` ### CLI ```sh firecrawl scrape 'platform-opentargets-org/associations/list_associations' \ --options '{"limit":10,"target":"BRAF"}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "platform-opentargets-org", "capability": "associations/list_associations", "options": { "limit": 10, "target": "BRAF" } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "platform-opentargets-org", "capability": "associations/list_associations", "options": { "limit": 10, "target": "BRAF" } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "disease": null, "indirect": false, "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "min_score": null, "next_cursor": "10", "observed_at_ms": 1792530868500, "order_by": "score", "release": "26.09", "results": [ { "datasource_scores": [ { "datasource": "uniprot_variants", "score": 0.9794 }, { "datasource": "genomics_england", "score": 0.9611 }, { "datasource": "eva", "score": 0.9528 }, { "datasource": "reactome", "score": 0.8275 }, { "datasource": "clingen", "score": 0.6079 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "europepmc", "score": 0.5315 }, { "datasource": "impc", "score": 0.452 }, { "datasource": "eva_somatic", "score": 0 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9442 }, { "datatype": "genetic_literature", "score": 0.856 }, { "datatype": "affected_pathway", "score": 0.8275 }, { "datatype": "literature", "score": 0.5315 }, { "datatype": "animal_model", "score": 0.452 }, { "datatype": "somatic_mutation", "score": 0 } ], "disease_id": "MONDO_0015280", "disease_name": "cardiofaciocutaneous syndrome", "ensembl_id": "ENSG00000157764", "score": 0.877, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0015280", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "integumentary system disorder", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9331 }, { "datasource": "reactome", "score": 0.9191 }, { "datasource": "eva", "score": 0.9032 }, { "datasource": "uniprot_variants", "score": 0.8898 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "impc", "score": 0.4383 }, { "datasource": "clingen", "score": 0.304 }, { "datasource": "europepmc", "score": 0.1247 } ], "datatype_scores": [ { "datatype": "affected_pathway", "score": 0.9191 }, { "datatype": "genetic_association", "score": 0.8767 }, { "datatype": "genetic_literature", "score": 0.823 }, { "datatype": "animal_model", "score": 0.4383 }, { "datatype": "literature", "score": 0.1247 } ], "disease_id": "MONDO_0018997", "disease_name": "Noonan syndrome", "ensembl_id": "ENSG00000157764", "score": 0.8381, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0018997", "symbol": "BRAF", "therapeutic_areas": [ "cardiovascular disorder", "genetic, familial or congenital disease", "hematologic disorder", "integumentary system disorder", "immune system disorder", "musculoskeletal or connective tissue disease", "phenotype" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9984 }, { "datasource": "clinical_precedence", "score": 0.9778 }, { "datasource": "intogen", "score": 0.9118 }, { "datasource": "eva", "score": 0.6991 }, { "datasource": "cancer_gene_census", "score": 0.6079 }, { "datasource": "crispr", "score": 0.4344 }, { "datasource": "eva_somatic", "score": 0.1824 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9984 }, { "datatype": "clinical", "score": 0.9778 }, { "datatype": "somatic_mutation", "score": 0.7964 }, { "datatype": "genetic_association", "score": 0.6991 }, { "datatype": "affected_pathway", "score": 0.4344 } ], "disease_id": "MONDO_0005105", "disease_name": "melanoma", "ensembl_id": "ENSG00000157764", "score": 0.8195, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0005105", "symbol": "BRAF", "therapeutic_areas": [ "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9486 }, { "datasource": "eva", "score": 0.9398 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3899 }, { "datasource": "europepmc", "score": 0.0122 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9398 }, { "datatype": "genetic_literature", "score": 0.8804 }, { "datatype": "animal_model", "score": 0.3899 }, { "datatype": "literature", "score": 0.0122 } ], "disease_id": "MONDO_0007265", "disease_name": "cardiofaciocutaneous syndrome 1", "ensembl_id": "ENSG00000157764", "score": 0.7636, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0007265", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "integumentary system disorder", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9437 }, { "datasource": "eva", "score": 0.9316 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3302 }, { "datasource": "europepmc", "score": 0.0334 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9316 }, { "datatype": "genetic_literature", "score": 0.8766 }, { "datatype": "animal_model", "score": 0.3302 }, { "datatype": "literature", "score": 0.0334 } ], "disease_id": "MONDO_0013379", "disease_name": "Noonan syndrome 7", "ensembl_id": "ENSG00000157764", "score": 0.759, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0013379", "symbol": "BRAF", "therapeutic_areas": [ "cardiovascular disorder", "genetic, familial or congenital disease", "hematologic disorder", "integumentary system disorder", "immune system disorder", "musculoskeletal or connective tissue disease", "phenotype" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9486 }, { "datasource": "eva", "score": 0.8914 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3629 }, { "datasource": "europepmc", "score": 0.0122 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.8914 }, { "datatype": "genetic_literature", "score": 0.8804 }, { "datatype": "animal_model", "score": 0.3629 }, { "datatype": "literature", "score": 0.0122 } ], "disease_id": "MONDO_0013380", "disease_name": "LEOPARD syndrome 3", "ensembl_id": "ENSG00000157764", "score": 0.756, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0013380", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9501 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "uniprot_variants", "score": 0.6079 }, { "datasource": "impc", "score": 0.4205 }, { "datasource": "europepmc", "score": 0.1067 }, { "datasource": "clingen", "score": 0.0061 }, { "datasource": "eva", "score": 0 } ], "datatype_scores": [ { "datatype": "genetic_literature", "score": 0.8219 }, { "datatype": "genetic_association", "score": 0.5583 }, { "datatype": "animal_model", "score": 0.4205 }, { "datatype": "literature", "score": 0.1067 } ], "disease_id": "MONDO_0007893", "disease_name": "Noonan syndrome with multiple lentigines", "ensembl_id": "ENSG00000157764", "score": 0.7507, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0007893", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9698 }, { "datasource": "clinical_precedence", "score": 0.9408 }, { "datasource": "eva", "score": 0.8521 }, { "datasource": "uniprot_variants", "score": 0.4449 }, { "datasource": "impc", "score": 0.3137 }, { "datasource": "uniprot_literature", "score": 0.304 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9698 }, { "datatype": "clinical", "score": 0.9408 }, { "datatype": "genetic_association", "score": 0.7707 }, { "datatype": "animal_model", "score": 0.3137 }, { "datatype": "genetic_literature", "score": 0.304 } ], "disease_id": "MONDO_0005575", "disease_name": "colorectal cancer", "ensembl_id": "ENSG00000157764", "score": 0.7489, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0005575", "symbol": "BRAF", "therapeutic_areas": [ "gastrointestinal disease", "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9856 }, { "datasource": "reactome", "score": 0.9834 }, { "datasource": "cancer_biomarkers", "score": 0.7599 }, { "datasource": "eva", "score": 0.4256 }, { "datasource": "clinical_precedence", "score": 0.423 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9856 }, { "datatype": "affected_pathway", "score": 0.9387 }, { "datatype": "genetic_association", "score": 0.4256 }, { "datatype": "clinical", "score": 0.423 } ], "disease_id": "MONDO_0004992", "disease_name": "cancer", "ensembl_id": "ENSG00000157764", "score": 0.7103, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0004992", "symbol": "BRAF", "therapeutic_areas": [ "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "eva", "score": 0.8521 }, { "datasource": "europepmc", "score": 0.8095 }, { "datasource": "uniprot_variants", "score": 0.7599 }, { "datasource": "genomics_england", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "clinical_precedence", "score": 0.1794 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.8337 }, { "datatype": "literature", "score": 0.8095 }, { "datatype": "genetic_literature", "score": 0.6079 }, { "datatype": "clinical", "score": 0.1794 } ], "disease_id": "MONDO_0008903", "disease_name": "lung cancer", "ensembl_id": "ENSG00000157764", "score": 0.7048, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0008903", "symbol": "BRAF", "therapeutic_areas": [ "respiratory or thoracic disease", "cancer or benign tumor", "phenotype" ] } ], "source_url": "https://platform.opentargets.org/target/ENSG00000157764/associations", "target": { "ensembl_id": "ENSG00000157764", "name": "B-Raf proto-oncogene, serine/threonine kinase", "symbol": "BRAF" }, "therapeutic_area": null, "total_count": 2928 } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### List associations - Capability: `associations/list_associations` - Description: Target-disease associations scored by Open Targets (0 to 1) with the score broken down by evidence type (genetic association, somatic mutation, known drug/clinical, pathways, RNA expression, literature, animal models) and by datasource. Give a target for its diseases (optionally within one therapeutic area), a disease for its targets, or both for one pair. Order by the overall score or one evidence type; `min_score` stops at a threshold. - Instructions: Rank diseases linked to a gene, rank targets for a disease (e.g. genetically supported targets for asthma), or check how strongly and by what evidence one target is linked to one disease. Follow with `list_evidence` for the underlying records. - Cost: 5 credits per call - Capability file: [List associations](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/associations/list_associations) Accepted options: - `cursor` (string): `next_cursor` from the previous page. Repeat the same inputs and `limit` with it. Pattern: ^[0-9]+$. Example: `next_cursor` - `disease` (string): Disease or phenotype: an ontology ID (`MONDO_0004979`, `EFO_0000270`, `EFO:0000270`, `HP_0002099`, `Orphanet_558`), an exact name or exact synonym (`asthma`, `T2DM`), or a platform.opentargets.org disease page URL. Retired EFO IDs follow to their replacement with a `disease_replaced` warning; other names fail as not_found listing the closest matches (use `search_diseases` to browse). Example: `MONDO_0004979` - `indirect` (boolean): Include indirect evidence, which propagates evidence on a disease's descendants up to it (e.g. Crohn's disease evidence counts for inflammatory bowel disease). Defaults to false for a target's diseases and true when a disease is given, as on the Open Targets pages. Example: `false` - `limit` (number): Rows per page, 1 to 100. Example: `25` - `min_score` (number): Stop at rows whose ranking score (overall, or the `order_by` evidence type) is below this. Example: `1` - `order_by` (string): Rank by the overall score or by one evidence type's score, descending. Example: `score` - `target` (string): Target: an HGNC symbol (`BRAF`), Ensembl gene ID (`ENSG00000157764`), UniProt accession (`P15056`), previous symbol, synonym (`HER2`, `p53`), approved name, or a platform.opentargets.org target page URL. Ambiguous synonyms fail as invalid_input naming the candidates. Example: `` - `therapeutic_area` (string): Only a target's diseases in this therapeutic area: a name or words of it (`cancer`, `respiratory`, `immune system disorder`) or its ID (`MONDO_0045024`). Not with `disease`. Example: `` Response schema example: ```json { "disease": null, "indirect": false, "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "min_score": null, "next_cursor": "10", "observed_at_ms": 1792530868500, "order_by": "score", "release": "26.09", "results": [ { "datasource_scores": [ { "datasource": "uniprot_variants", "score": 0.9794 }, { "datasource": "genomics_england", "score": 0.9611 }, { "datasource": "eva", "score": 0.9528 }, { "datasource": "reactome", "score": 0.8275 }, { "datasource": "clingen", "score": 0.6079 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "europepmc", "score": 0.5315 }, { "datasource": "impc", "score": 0.452 }, { "datasource": "eva_somatic", "score": 0 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9442 }, { "datatype": "genetic_literature", "score": 0.856 }, { "datatype": "affected_pathway", "score": 0.8275 }, { "datatype": "literature", "score": 0.5315 }, { "datatype": "animal_model", "score": 0.452 }, { "datatype": "somatic_mutation", "score": 0 } ], "disease_id": "MONDO_0015280", "disease_name": "cardiofaciocutaneous syndrome", "ensembl_id": "ENSG00000157764", "score": 0.877, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0015280", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "integumentary system disorder", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9331 }, { "datasource": "reactome", "score": 0.9191 }, { "datasource": "eva", "score": 0.9032 }, { "datasource": "uniprot_variants", "score": 0.8898 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "impc", "score": 0.4383 }, { "datasource": "clingen", "score": 0.304 }, { "datasource": "europepmc", "score": 0.1247 } ], "datatype_scores": [ { "datatype": "affected_pathway", "score": 0.9191 }, { "datatype": "genetic_association", "score": 0.8767 }, { "datatype": "genetic_literature", "score": 0.823 }, { "datatype": "animal_model", "score": 0.4383 }, { "datatype": "literature", "score": 0.1247 } ], "disease_id": "MONDO_0018997", "disease_name": "Noonan syndrome", "ensembl_id": "ENSG00000157764", "score": 0.8381, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0018997", "symbol": "BRAF", "therapeutic_areas": [ "cardiovascular disorder", "genetic, familial or congenital disease", "hematologic disorder", "integumentary system disorder", "immune system disorder", "musculoskeletal or connective tissue disease", "phenotype" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9984 }, { "datasource": "clinical_precedence", "score": 0.9778 }, { "datasource": "intogen", "score": 0.9118 }, { "datasource": "eva", "score": 0.6991 }, { "datasource": "cancer_gene_census", "score": 0.6079 }, { "datasource": "crispr", "score": 0.4344 }, { "datasource": "eva_somatic", "score": 0.1824 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9984 }, { "datatype": "clinical", "score": 0.9778 }, { "datatype": "somatic_mutation", "score": 0.7964 }, { "datatype": "genetic_association", "score": 0.6991 }, { "datatype": "affected_pathway", "score": 0.4344 } ], "disease_id": "MONDO_0005105", "disease_name": "melanoma", "ensembl_id": "ENSG00000157764", "score": 0.8195, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0005105", "symbol": "BRAF", "therapeutic_areas": [ "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9486 }, { "datasource": "eva", "score": 0.9398 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3899 }, { "datasource": "europepmc", "score": 0.0122 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9398 }, { "datatype": "genetic_literature", "score": 0.8804 }, { "datatype": "animal_model", "score": 0.3899 }, { "datatype": "literature", "score": 0.0122 } ], "disease_id": "MONDO_0007265", "disease_name": "cardiofaciocutaneous syndrome 1", "ensembl_id": "ENSG00000157764", "score": 0.7636, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0007265", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "integumentary system disorder", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9437 }, { "datasource": "eva", "score": 0.9316 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3302 }, { "datasource": "europepmc", "score": 0.0334 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.9316 }, { "datatype": "genetic_literature", "score": 0.8766 }, { "datatype": "animal_model", "score": 0.3302 }, { "datatype": "literature", "score": 0.0334 } ], "disease_id": "MONDO_0013379", "disease_name": "Noonan syndrome 7", "ensembl_id": "ENSG00000157764", "score": 0.759, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0013379", "symbol": "BRAF", "therapeutic_areas": [ "cardiovascular disorder", "genetic, familial or congenital disease", "hematologic disorder", "integumentary system disorder", "immune system disorder", "musculoskeletal or connective tissue disease", "phenotype" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9486 }, { "datasource": "eva", "score": 0.8914 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "impc", "score": 0.3629 }, { "datasource": "europepmc", "score": 0.0122 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.8914 }, { "datatype": "genetic_literature", "score": 0.8804 }, { "datatype": "animal_model", "score": 0.3629 }, { "datatype": "literature", "score": 0.0122 } ], "disease_id": "MONDO_0013380", "disease_name": "LEOPARD syndrome 3", "ensembl_id": "ENSG00000157764", "score": 0.756, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0013380", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "genomics_england", "score": 0.9501 }, { "datasource": "gene2phenotype", "score": 0.6079 }, { "datasource": "orphanet", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "uniprot_variants", "score": 0.6079 }, { "datasource": "impc", "score": 0.4205 }, { "datasource": "europepmc", "score": 0.1067 }, { "datasource": "clingen", "score": 0.0061 }, { "datasource": "eva", "score": 0 } ], "datatype_scores": [ { "datatype": "genetic_literature", "score": 0.8219 }, { "datatype": "genetic_association", "score": 0.5583 }, { "datatype": "animal_model", "score": 0.4205 }, { "datatype": "literature", "score": 0.1067 } ], "disease_id": "MONDO_0007893", "disease_name": "Noonan syndrome with multiple lentigines", "ensembl_id": "ENSG00000157764", "score": 0.7507, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0007893", "symbol": "BRAF", "therapeutic_areas": [ "genetic, familial or congenital disease", "cardiovascular disorder", "musculoskeletal or connective tissue disease" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9698 }, { "datasource": "clinical_precedence", "score": 0.9408 }, { "datasource": "eva", "score": 0.8521 }, { "datasource": "uniprot_variants", "score": 0.4449 }, { "datasource": "impc", "score": 0.3137 }, { "datasource": "uniprot_literature", "score": 0.304 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9698 }, { "datatype": "clinical", "score": 0.9408 }, { "datatype": "genetic_association", "score": 0.7707 }, { "datatype": "animal_model", "score": 0.3137 }, { "datatype": "genetic_literature", "score": 0.304 } ], "disease_id": "MONDO_0005575", "disease_name": "colorectal cancer", "ensembl_id": "ENSG00000157764", "score": 0.7489, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0005575", "symbol": "BRAF", "therapeutic_areas": [ "gastrointestinal disease", "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "europepmc", "score": 0.9856 }, { "datasource": "reactome", "score": 0.9834 }, { "datasource": "cancer_biomarkers", "score": 0.7599 }, { "datasource": "eva", "score": 0.4256 }, { "datasource": "clinical_precedence", "score": 0.423 } ], "datatype_scores": [ { "datatype": "literature", "score": 0.9856 }, { "datatype": "affected_pathway", "score": 0.9387 }, { "datatype": "genetic_association", "score": 0.4256 }, { "datatype": "clinical", "score": 0.423 } ], "disease_id": "MONDO_0004992", "disease_name": "cancer", "ensembl_id": "ENSG00000157764", "score": 0.7103, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0004992", "symbol": "BRAF", "therapeutic_areas": [ "cancer or benign tumor" ] }, { "datasource_scores": [ { "datasource": "eva", "score": 0.8521 }, { "datasource": "europepmc", "score": 0.8095 }, { "datasource": "uniprot_variants", "score": 0.7599 }, { "datasource": "genomics_england", "score": 0.6079 }, { "datasource": "uniprot_literature", "score": 0.6079 }, { "datasource": "clinical_precedence", "score": 0.1794 } ], "datatype_scores": [ { "datatype": "genetic_association", "score": 0.8337 }, { "datatype": "literature", "score": 0.8095 }, { "datatype": "genetic_literature", "score": 0.6079 }, { "datatype": "clinical", "score": 0.1794 } ], "disease_id": "MONDO_0008903", "disease_name": "lung cancer", "ensembl_id": "ENSG00000157764", "score": 0.7048, "source_url": "https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0008903", "symbol": "BRAF", "therapeutic_areas": [ "respiratory or thoracic disease", "cancer or benign tumor", "phenotype" ] } ], "source_url": "https://platform.opentargets.org/target/ENSG00000157764/associations", "target": { "ensembl_id": "ENSG00000157764", "name": "B-Raf proto-oncogene, serine/threonine kinase", "symbol": "BRAF" }, "therapeutic_area": null, "total_count": 2928 } ``` ### Get target - Capability: `targets/get_target` - Description: One drug target (human gene) from Open Targets: approved symbol and name, Ensembl ID, biotype, synonyms and previous symbols, UniProt function text, genomic location, ChEMBL target class, tractability by modality (small molecule, antibody, PROTAC, other), subcellular locations, safety liabilities with effects, tissues and sources, chemical probes, gnomAD loss-of-function constraint, core essentiality, and UniProt, HGNC, ChEMBL and PDB cross-references. Accepts a symbol, Ensembl ID, UniProt accession, synonym or target page URL; `matched_on` says how the input matched. - Instructions: Profile a gene or protein as a drug target: is it tractable and by which modality, what safety liabilities are known, where is it in the cell, which chemical probes exist. Follow with `list_associations` for its diseases or `list_drugs` for its drugs. - Cost: 5 credits per call - Capability file: [Get target](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/targets/get_target) Accepted options: - `target` (string, required): Target: an HGNC symbol (`BRAF`), Ensembl gene ID (`ENSG00000157764`), UniProt accession (`P15056`), previous symbol, synonym (`HER2`, `p53`), approved name, or a platform.opentargets.org target page URL. Ambiguous synonyms fail as invalid_input naming the candidates. Example: `` Response schema example: ```json { "biotype": "protein_coding", "chemical_probes": [ { "chembl_id": "CHEMBL525191", "high_quality": true, "id": "GDC-0879", "mechanisms": [ "inhibitor" ] }, { "chembl_id": null, "high_quality": true, "id": "P4B", "mechanisms": [ "degrader" ] } ], "cross_references": { "chembl": [ "CHEMBL5145" ], "hgnc": [ "HGNC:1097" ], "pdb": [ "1UWH", "1UWJ", "2FB8", "2L05", "3C4C", "3D4Q", "3IDP", "3II5", "3NY5", "3OG7", "3PPJ", "3PPK", "3PRF", "3PRI", "3PSB", "3PSD", "3Q4C", "3Q96", "3SKC", "3TV4" ], "pdb_count": 131, "uniprot": [ "P15056" ] }, "ensembl_id": "ENSG00000157764", "essential": false, "function": [ "Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789, ECO:0000305}." ], "genomic_location": { "chromosome": "7", "end": 140925199, "start": 140719327, "strand": "negative" }, "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "lof_constraint": { "category": "very high", "oe": 0.153, "oe_upper": 0.2323 }, "matched_on": "symbol", "name": "B-Raf proto-oncogene, serine/threonine kinase", "observed_at_ms": 1792530866446, "previous_symbols": [], "query": "BRAF", "release": "26.09", "safety_liabilities": [ { "biosamples": [ "cardiovascular system" ], "datasource": "Force et al. (2011)", "effects": [], "event": "heart disease", "event_id": "MONDO_0005267", "pmid": "21283106", "url": null } ], "source_url": "https://platform.opentargets.org/target/ENSG00000157764", "subcellular_locations": [ { "location": "Nucleus", "source": "uniprot", "term_id": "SL-0191" }, { "location": "Cytoplasm", "source": "uniprot", "term_id": "SL-0086" }, { "location": "Cell membrane", "source": "uniprot", "term_id": "SL-0039" }, { "location": "Cytosol", "source": "HPA_main", "term_id": "SL-0091" }, { "location": "Vesicles", "source": "HPA_main", "term_id": "SL-0498" }, { "location": "Basal body", "source": "HPA_additional", "term_id": null }, { "location": "Centriolar satellite", "source": "HPA_additional", "term_id": "SL-0485" }, { "location": "End piece", "source": "HPA_additional", "term_id": null }, { "location": "Mid piece", "source": "HPA_additional", "term_id": null }, { "location": "Plasma membrane", "source": "HPA_additional", "term_id": "SL-0039" }, { "location": "Primary cilium", "source": "HPA_additional", "term_id": null }, { "location": "Principal piece", "source": "HPA_additional", "term_id": null } ], "symbol": "BRAF", "synonyms": [ "BRAF1", "RAFB1", "BRAF-1", "B-RAF1", "B-raf", "NS7", "Serine/threonine-protein kinase B-raf", "Proto-oncogene B-Raf", "p94", "v-Raf murine sarcoma viral oncogene homolog B1", "94 kDa B-raf protein", "B-Raf proto-oncogene serine/threonine-protein kinase (p94)", "B-Raf serine/threonine-protein", "murine sarcoma viral (v-raf) oncogene homolog B1", "v-raf murine sarcoma viral oncogene homolog B" ], "target_class": [ "Enzyme", "Kinase", "Protein Kinase", "TKL protein kinase group", "TKL protein kinase RAF family" ], "tractability": { "antibody": [ "UniProt loc high conf", "GO CC high conf", "Human Protein Atlas loc" ], "other_modalities": [], "protac": [ "Literature", "UniProt Ubiquitination", "Database Ubiquitination", "Half-life Data", "Small Molecule Binder" ], "small_molecule": [ "Approved Drug", "Structure with Ligand", "High-Quality Ligand", "High-Quality Pocket", "Druggable Family" ] } } ``` ### List drugs - Capability: `drugs/list_drugs` - Description: Known drugs and clinical candidates from Open Targets clinical reports (ClinicalTrials.gov, FDA, EMA, PMDA, DailyMed, ChEMBL, TTD): for a target, the drugs acting on it with their indications; for a disease, the drugs developed for it; for both, the drugs for that disease that act on that target. Each row has the ChEMBL ID, name, type, highest harmonised clinical stage, mechanisms of action with their targets, and up to 5 supporting reports with IDs, status and links. Highest stage first; `min_stage` filters. - Instructions: Find approved and investigational drugs for a target (e.g. what modulates PCSK9) or for a disease, or check whether any drug for a disease works through a given target. - Cost: 5 credits per call - Capability file: [List drugs](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/drugs/list_drugs) Accepted options: - `cursor` (string): `next_cursor` from the previous page. Repeat the same inputs and `limit` with it. Pattern: ^[0-9]+$. Example: `next_cursor` - `disease` (string): Disease or phenotype: an ontology ID (`MONDO_0004979`, `EFO_0000270`, `EFO:0000270`, `HP_0002099`, `Orphanet_558`), an exact name or exact synonym (`asthma`, `T2DM`), or a platform.opentargets.org disease page URL. Retired EFO IDs follow to their replacement with a `disease_replaced` warning; other names fail as not_found listing the closest matches (use `search_diseases` to browse). Example: `MONDO_0004979` - `limit` (number): Rows per page, 1 to 100. Example: `25` - `min_stage` (string): Only drugs at this stage or later; PHASE_3 includes PREAPPROVAL, PHASE_2 includes PHASE_2_3, PHASE_1 includes PHASE_1_2. Example: `PHASE_1` - `target` (string): Target: an HGNC symbol (`BRAF`), Ensembl gene ID (`ENSG00000157764`), UniProt accession (`P15056`), previous symbol, synonym (`HER2`, `p53`), approved name, or a platform.opentargets.org target page URL. Ambiguous synonyms fail as invalid_input naming the candidates. Example: `` Response schema example: ```json { "disease": null, "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "min_stage": "APPROVAL", "next_cursor": null, "observed_at_ms": 1792530871595, "release": "26.09", "results": [ { "chembl_id": "CHEMBL2109540", "drug_max_stage": "APPROVAL", "drug_type": "Antibody", "indication_count": 18, "indications": [ { "id": "MONDO_0004995", "name": "cardiovascular disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005010", "name": "coronary artery disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005439", "name": "familial hypercholesterolemia", "stage": "APPROVAL" }, { "id": "HP_0003124", "name": "Hypercholesterolemia", "stage": "APPROVAL" }, { "id": "MONDO_0002525", "name": "inherited lipid metabolism disorder", "stage": "APPROVAL" }, { "id": "MONDO_0004781", "name": "acute myocardial infarction", "stage": "PHASE_3" }, { "id": "MONDO_0018328", "name": "homozygous familial hypercholesterolemia", "stage": "PHASE_3" }, { "id": "MONDO_0005147", "name": "type 1 diabetes mellitus", "stage": "PHASE_3" }, { "id": "MONDO_0005148", "name": "type 2 diabetes mellitus", "stage": "PHASE_3" }, { "id": "HP_0100806", "name": "Sepsis", "stage": "PHASE_2_3" } ], "mechanisms": [ { "action_type": "INHIBITOR", "mechanism": "Subtilisin/kexin type 9 inhibitor", "targets": [ { "ensembl_id": "ENSG00000169174", "symbol": "PCSK9" } ] } ], "name": "ALIROCUMAB", "references": [ { "id": "7628ee7e074c32c90e1d03587e7d39bd2c305c6d563868e60ca55d3710cc560c", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "7af642544ad40fbf91870f46c3b81713bc115caf66d5fec27d0656a5a80c6c9e", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "emea/h/c/003882", "source": "EMA Human Drugs", "stage": "APPROVAL", "status": null, "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/praluent" }, { "id": "446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4", "source": "DailyMed", "stage": "APPROVAL", "status": null, "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4" }, { "id": "c10ax14", "source": "ATC", "stage": "APPROVAL", "status": null, "url": "https://www.whocc.no/atc_ddd_index/?code=C10AX14" } ], "report_count": 81, "source_url": "https://platform.opentargets.org/drug/CHEMBL2109540", "stage": "APPROVAL" }, { "chembl_id": "CHEMBL2364655", "drug_max_stage": "APPROVAL", "drug_type": "Antibody", "indication_count": 27, "indications": [ { "id": "MONDO_0004995", "name": "cardiovascular disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005010", "name": "coronary artery disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005439", "name": "familial hypercholesterolemia", "stage": "APPROVAL" }, { "id": "MONDO_0018328", "name": "homozygous familial hypercholesterolemia", "stage": "APPROVAL" }, { "id": "HP_0003124", "name": "Hypercholesterolemia", "stage": "APPROVAL" }, { "id": "MONDO_0002525", "name": "inherited lipid metabolism disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005068", "name": "myocardial infarction", "stage": "APPROVAL" }, { "id": "MONDO_0005098", "name": "stroke disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005542", "name": "acute coronary syndrome", "stage": "PHASE_3" }, { "id": "Orphanet_79211", "name": "Combined hyperlipidemia", "stage": "PHASE_3" } ], "mechanisms": [ { "action_type": "INHIBITOR", "mechanism": "Subtilisin/kexin type 9 inhibitor", "targets": [ { "ensembl_id": "ENSG00000169174", "symbol": "PCSK9" } ] } ], "name": "EVOLOCUMAB", "references": [ { "id": "1e079d34c7ece84727959e6fdbdbd7086f3bef63c69483437ef797466602b91c", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "7f4cfcadff0ae916b729408d242bb57386bd67e7b97e13f6b5dda21838d6ceff", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "emea/h/c/003766", "source": "EMA Human Drugs", "stage": "APPROVAL", "status": null, "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/repatha" }, { "id": "709338ae-ab8f-44a9-b7d5-abaabec3493a", "source": "DailyMed", "stage": "APPROVAL", "status": null, "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=709338ae-ab8f-44a9-b7d5-abaabec3493a" }, { "id": "cd61e902-166d-4aa6-9f3c-a18c1008d07e", "source": "DailyMed", "stage": "APPROVAL", "status": null, "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd61e902-166d-4aa6-9f3c-a18c1008d07e" } ], "report_count": 113, "source_url": "https://platform.opentargets.org/drug/CHEMBL2364655", "stage": "APPROVAL" }, { "chembl_id": "CHEMBL3990033", "drug_max_stage": "APPROVAL", "drug_type": "Oligonucleotide", "indication_count": 13, "indications": [ { "id": "MONDO_0004995", "name": "cardiovascular disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005439", "name": "familial hypercholesterolemia", "stage": "APPROVAL" }, { "id": "HP_0003124", "name": "Hypercholesterolemia", "stage": "APPROVAL" }, { "id": "MONDO_0002525", "name": "inherited lipid metabolism disorder", "stage": "APPROVAL" }, { "id": "MONDO_0005542", "name": "acute coronary syndrome", "stage": "PHASE_3" }, { "id": "MONDO_0005311", "name": "atherosclerosis", "stage": "PHASE_3" }, { "id": "MONDO_0005015", "name": "diabetes mellitus", "stage": "PHASE_3" }, { "id": "MONDO_0018328", "name": "homozygous familial hypercholesterolemia", "stage": "PHASE_3" }, { "id": "EFO_0008586", "name": "Non-ST Elevation Myocardial Infarction", "stage": "PHASE_3" }, { "id": "EFO_0008585", "name": "ST Elevation Myocardial Infarction", "stage": "PHASE_3" } ], "mechanisms": [ { "action_type": "RNAI INHIBITOR", "mechanism": "PCSK9 mRNA RNAi inhibitor", "targets": [ { "ensembl_id": "ENSG00000169174", "symbol": "PCSK9" } ] } ], "name": "INCLISIRAN", "references": [ { "id": "emea/h/c/005333", "source": "EMA Human Drugs", "stage": "APPROVAL", "status": null, "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio" }, { "id": "c10ax16", "source": "ATC", "stage": "APPROVAL", "status": null, "url": "https://www.whocc.no/atc_ddd_index/?code=C10AX16" }, { "id": "d00coj/familial hypercholesterolemia", "source": "TTD", "stage": "APPROVAL", "status": null, "url": "https://ttd.idrblab.cn/data/drug/details/D00COJ" }, { "id": "NCT06338293", "source": "ClinicalTrials.gov", "stage": "PHASE_4", "status": "RECRUITING", "url": "https://clinicaltrials.gov/study/NCT06338293" }, { "id": "NCT06421363", "source": "ClinicalTrials.gov", "stage": "PHASE_4", "status": "NOT_YET_RECRUITING", "url": "https://clinicaltrials.gov/study/NCT06421363" } ], "report_count": 34, "source_url": "https://platform.opentargets.org/drug/CHEMBL3990033", "stage": "APPROVAL" }, { "chembl_id": "CHEMBL5095052", "drug_max_stage": "APPROVAL", "drug_type": "Oligonucleotide", "indication_count": 5, "indications": [ { "id": "MONDO_0005311", "name": "atherosclerosis", "stage": "APPROVAL" }, { "id": "MONDO_0005439", "name": "familial hypercholesterolemia", "stage": "APPROVAL" }, { "id": "HP_0003124", "name": "Hypercholesterolemia", "stage": "APPROVAL" }, { "id": "MONDO_0004995", "name": "cardiovascular disorder", "stage": "PHASE_3" }, { "id": "EFO_1001483", "name": "non-obstructive coronary artery disease", "stage": "PHASE_3" } ], "mechanisms": [ { "action_type": "RNAI INHIBITOR", "mechanism": "PCSK9 mRNA rnai inhibitor", "targets": [ { "ensembl_id": "ENSG00000169174", "symbol": "PCSK9" } ] } ], "name": "INCLISIRAN SODIUM", "references": [ { "id": "3c3a48297d98c0dbc2cab62b85b4190ed4b70e3daf1b227eaa4b538680b1d0ba", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "cc3aab896f6d6757c59b1f06c1d0179a34d96717d26f87625fecb240f6334d5f", "source": "PMDA", "stage": "APPROVAL", "status": null, "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html" }, { "id": "label/2021/214012lbl.pdf", "source": "FDA", "stage": "APPROVAL", "status": null, "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf" }, { "id": "NCT06386419", "source": "ClinicalTrials.gov", "stage": "PHASE_4", "status": "COMPLETED", "url": "https://clinicaltrials.gov/study/NCT06386419" }, { "id": "NCT03397121", "source": "ClinicalTrials.gov", "stage": "PHASE_3", "status": "COMPLETED", "url": "https://clinicaltrials.gov/study/NCT03397121" } ], "report_count": 9, "source_url": "https://platform.opentargets.org/drug/CHEMBL5095052", "stage": "APPROVAL" } ], "source_url": "https://platform.opentargets.org/target/ENSG00000169174", "target": { "ensembl_id": "ENSG00000169174", "name": "proprotein convertase subtilisin/kexin type 9", "symbol": "PCSK9" }, "total_count": 4 } ``` ### List evidence - Capability: `evidence/list_evidence` - Description: The evidence records behind one Open Targets target-disease association, highest score first: datasource and evidence type, score, the disease as the source named it, PubMed and PMC IDs, variant and rsID, GWAS study, drug and clinical stage, direction of effect on target and trait, ClinVar significance, p-value, odds ratio, beta, sample size and source links. Filter to chosen datasources. - Instructions: See why a target is associated with a disease: the GWAS credible sets, rare-variant reports, somatic drivers, clinical precedence or papers behind a `list_associations` score. - Cost: 5 credits per call - Capability file: [List evidence](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/evidence/list_evidence) Accepted options: - `cursor` (string): `next_cursor` from the previous page. Repeat the same inputs and `limit` with it. Pattern: ^[0-9]+$. Example: `next_cursor` - `datasources` (string[]): Only these datasources (`datasource_scores` in `list_associations` shows which have evidence). Example: `["datasource_scores"]` - `disease` (string): Disease or phenotype: an ontology ID (`MONDO_0004979`, `EFO_0000270`, `EFO:0000270`, `HP_0002099`, `Orphanet_558`), an exact name or exact synonym (`asthma`, `T2DM`), or a platform.opentargets.org disease page URL. Retired EFO IDs follow to their replacement with a `disease_replaced` warning; other names fail as not_found listing the closest matches (use `search_diseases` to browse). Example: `MONDO_0004979` - `indirect` (boolean): Include evidence on the disease's descendants, as the evidence page does. Example: `false` - `limit` (number): Rows per page, 1 to 50. Example: `25` - `target` (string): Target: an HGNC symbol (`BRAF`), Ensembl gene ID (`ENSG00000157764`), UniProt accession (`P15056`), previous symbol, synonym (`HER2`, `p53`), approved name, or a platform.opentargets.org target page URL. Ambiguous synonyms fail as invalid_input naming the candidates. Give with `disease`, or give `url`. Example: `` - `url` (string): Evidence page URL, e.g. https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0005439. Instead of `target` and `disease`. Example: `` Response schema example: ```json { "datasources": null, "disease": { "id": "MONDO_0005439", "name": "familial hypercholesterolemia" }, "indirect": true, "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "next_cursor": "10", "observed_at_ms": 1792530870307, "release": "26.09", "results": [ { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "green", "datasource": "genomics_england", "datatype": "genetic_literature", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Familial Hypercholesterolemia", "disease_id": "MONDO_0005439", "disease_name": "familial hypercholesterolemia", "drug_chembl_id": null, "drug_name": null, "id": "049c24d14c0dcbdac57a3bb3166302d42392ab27", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "23433573" ], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0005439", "study_id": "6", "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "green", "datasource": "genomics_england", "datatype": "genetic_literature", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Low density lipoprotein cholesterol level QTL 1", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "0d165d5d08921f48bfd58d738aae7ac3811cb25e", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "12730697", "14727179", "16909389", "27604308", "15772090", "15654334" ], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": "302", "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "green", "datasource": "genomics_england", "datatype": "genetic_literature", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Familial Hypercholesterolaemia", "disease_id": "MONDO_0005439", "disease_name": "familial hypercholesterolemia", "drug_chembl_id": null, "drug_name": null, "id": "149102e8512e50a1fe1c013fd148f0a691a7c569", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "23433573" ], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0005439", "study_id": "6", "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": "APPROVAL", "confidence": null, "datasource": "clinical_precedence", "datatype": "clinical", "direction_on_target": "LoF", "direction_on_trait": "protect", "disease_from_source": "familial hypercholesterolemia", "disease_id": "MONDO_0005439", "disease_name": "familial hypercholesterolemia", "drug_chembl_id": "CHEMBL2109540", "drug_name": "ALIROCUMAB", "id": "195fa90f713a0f687a8be5f4db7095057e0a26fe", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0005439", "study_id": null, "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "green", "datasource": "genomics_england", "datatype": "genetic_literature", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Low density lipoprotein cholesterol level QTL 1", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "1c730d170e276b7bfc78c68076664cc3d3f29488", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "12730697", "14727179", "16909389", "27604308", "15772090", "15654334", "26541928" ], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": "467", "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": "APPROVAL", "confidence": null, "datasource": "clinical_precedence", "datatype": "clinical", "direction_on_target": "LoF", "direction_on_trait": "protect", "disease_from_source": "homozygous familial hypercholesterolemia", "disease_id": "MONDO_0018328", "disease_name": "homozygous familial hypercholesterolemia", "drug_chembl_id": "CHEMBL2364655", "drug_name": "EVOLOCUMAB", "id": "1f0984e1238adf7b761cf46527180a306e1a12f5", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0018328", "study_id": null, "variant_id": null }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "high", "datasource": "uniprot_variants", "datatype": "genetic_association", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Hypercholesterolemia, familial, 3", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "1f85abbd67b01c63e941e795ffe9e241d8a3c023", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [], "preprints": [], "publication_year": null, "rsid": "rs374603772", "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": null, "variant_id": "1_55058630_C_T" }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "high", "datasource": "uniprot_variants", "datatype": "genetic_association", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Hypercholesterolemia, familial, 3", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "3a4d941e438f2ae59900603e7e7def56799749a4", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "12730697" ], "preprints": [], "publication_year": null, "rsid": "rs28942112", "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": null, "variant_id": "1_55052400_T_C" }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "high", "datasource": "uniprot_variants", "datatype": "genetic_association", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Hypercholesterolemia, familial, 3", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "3aef1dd9a76160c475b28403c5fdf9195cad2e74", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "12730697" ], "preprints": [], "publication_year": null, "rsid": "rs28942111", "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": null, "variant_id": "1_55044016_T_A" }, { "beta": null, "clinical_significances": [], "clinical_stage": null, "confidence": "green", "datasource": "genomics_england", "datatype": "genetic_literature", "direction_on_target": null, "direction_on_trait": null, "disease_from_source": "Hypercholesterolemia, familial, 3", "disease_id": "MONDO_0011369", "disease_name": "hypercholesterolemia, autosomal dominant, 3", "drug_chembl_id": null, "drug_name": null, "id": "41278ec76e75b45481344621eea89129ceb0965b", "links": [], "odds_ratio": null, "p_value": null, "pmcids": [], "pmids": [ "12730697", "14727179", "16909389", "27604308", "15772090", "15654334", "26541928" ], "preprints": [], "publication_year": null, "rsid": null, "sample_size": null, "score": 1, "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0011369", "study_id": "467", "variant_id": null } ], "source_url": "https://platform.opentargets.org/evidence/ENSG00000169174/MONDO_0005439", "target": { "ensembl_id": "ENSG00000169174", "name": "proprotein convertase subtilisin/kexin type 9", "symbol": "PCSK9" }, "total_count": 4038 } ``` ### Search diseases - Capability: `diseases/search_diseases` - Description: Search Open Targets diseases and phenotypes (EFO, MONDO, HP, Orphanet terms) by free text, or read one by ontology ID or disease page URL. Each result has its ID, name, description, therapeutic areas, exact synonyms, cross-references to other vocabularies (MeSH, DOID, ICD10, OMIM, UMLS) and the retired IDs it replaces. Retired EFO IDs (e.g. EFO_0000270) are followed to the current record through EBI OLS. - Instructions: Find the right disease ID before `list_associations`, `list_evidence` or `list_drugs`, map a disease between vocabularies, or find what a retired EFO ID is now called. - Cost: 5 credits per call - Capability file: [Search diseases](https://firecrawl.dev/alexandria/agents/providers/platform-opentargets-org/diseases/search_diseases) Accepted options: - `cursor` (string): `next_cursor` from the previous page. Repeat the same inputs and `limit` with it. Pattern: ^[0-9]+$. Example: `next_cursor` - `limit` (number): Rows per page, 1 to 50. Example: `10` - `query` (string, required): Free text (`asthma`, `breast cancer`, `crohn's disease`), an ontology ID (`MONDO_0004979`, `EFO:0000270`, `HP_0002099`) or a disease page URL. Example: `` Response schema example: ```json { "license": { "attribution": "Open Targets Platform, release 26.09 (https://platform.opentargets.org). Cite: Buniello A. et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128", "name": "CC0 1.0", "url": "https://creativecommons.org/publicdomain/zero/1.0/" }, "next_cursor": "5", "observed_at_ms": 1792530867157, "query": "asthma", "release": "26.09", "results": [ { "cross_references": [ "DOID:2841", "HP:0002099", "ICD10CM:J45", "ICD10WHO:J45", "ICD9:493", "ICD9:493.81", "ICD9:493.9", "MEDGEN:2109", "MESH:D001249", "NCIT:C28397", "SCTID:31387002", "UMLS:C0004096", "icd11.foundation:1656445230" ], "description": "A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.", "id": "MONDO_0004979", "name": "asthma", "obsolete_ids": [ "HP_0002099", "EFO_0000270" ], "source_url": "https://platform.opentargets.org/disease/MONDO_0004979", "synonyms": [ "Bronchial asthma", "ASTHMA NOS W (AC) EXAC", "Airway hyperreactivity", "Asthma (disorder)", "Asthma NOS", "Asthma NOS (disorder)", "Asthma unspecified", "Asthma unspecified (disorder)", "Asthma, Bronchial", "Asthma, unspecified", "Asthma, unspecified type, with acute exacerbation", "Asthma, unspecified type, without mention of status asthmaticus", "Asthmas", "Asthmatic", "BA", "BHR - Bronchial hyperreactivity", "Bronchial Hyperreactivities", "Bronchial hyperreactivity", "Bronchial hyperresponsiveness", "Bronchial hypersensitivity", "DUST PNEUMONOPATHY NEC", "Exercise induced asthma", "Exercise-induced asthma", "Exercise-induced asthma (disorder)", "Hyperreactive airway disease", "Hyperreactive airways disease", "Hyperreactivities, Bronchial", "Hyperreactivity, Bronchial", "Other forms of asthma", "Pneumonopathy due to inhalation of other dust", "Pneumopathy due to inhalation of other dust", "Pneumopathy due to inhalation of other dust (disorder)", "Pneumopathy due to inhalation of other dust NOS", "Pneumopathy due to inhalation of other dust NOS (disorder)", "chronic obstructive asthma", "chronic obstructive asthma with acute exacerbation", "chronic obstructive asthma with status asthmaticus" ], "therapeutic_areas": [ { "id": "EFO_0000651", "name": "phenotype" }, { "id": "OTAR_0000010", "name": "respiratory or thoracic disease" } ] }, { "cross_references": [ "DOID:0080815", "MEDGEN:538550", "SCTID:233678006", "UMLS:C0264408" ], "description": "Asthma that starts in childhood.", "id": "MONDO_0005405", "name": "childhood onset asthma", "obsolete_ids": [ "EFO_0004591" ], "source_url": "https://platform.opentargets.org/disease/MONDO_0005405", "synonyms": [ "asthma of childhood", "childhood asthma", "paediatric asthma", "pediatric asthma", "childhood-onset asthma" ], "therapeutic_areas": [ { "id": "EFO_0000651", "name": "phenotype" }, { "id": "OTAR_0000010", "name": "respiratory or thoracic disease" } ] }, { "cross_references": [ "DOID:9415", "ICD9:493.0", "MEDGEN:102343", "SCTID:389145006", "UMLS:C0155877", "icd11.foundation:1870104478" ], "description": "A asthma with a basis in a pathological type I hypersensitivity reaction.", "id": "MONDO_0004784", "name": "allergic asthma", "obsolete_ids": [], "source_url": "https://platform.opentargets.org/disease/MONDO_0004784", "synonyms": [ "allergic form of asthma" ], "therapeutic_areas": [ { "id": "OTAR_0000010", "name": "respiratory or thoracic disease" }, { "id": "EFO_0000651", "name": "phenotype" }, { "id": "MONDO_0005046", "name": "immune system disorder" } ] }, { "cross_references": [], "description": "The age at which asthma manifestations first appear.", "id": "OBA_2001001", "name": "age of onset of asthma", "obsolete_ids": [], "source_url": "https://platform.opentargets.org/disease/OBA_2001001", "synonyms": [ "age asthma symptoms begin", "age at onset of asthma" ], "therapeutic_areas": [ { "id": "EFO_0001444", "name": "measurement" } ] }, { "cross_references": [ "MedDRA:10003638" ], "description": "An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold.", "id": "EFO_0010638", "name": "atopic asthma", "obsolete_ids": [], "source_url": "https://platform.opentargets.org/disease/EFO_0010638", "synonyms": [ "allergic asthma" ], "therapeutic_areas": [ { "id": "EFO_0000651", "name": "phenotype" }, { "id": "OTAR_0000010", "name": "respiratory or thoracic disease" } ] } ], "source_url": "https://platform.opentargets.org/search?q=asthma&entities=disease", "total_count": 302 } ```